Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 279

1.

Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism.

Abt ER, Rosser EW, Durst MA, Lok V, Poddar S, Le TM, Cho A, Kim W, Wei L, Song J, Capri JR, Xu S, Wu N, Slavik R, Jung ME, Damoiseaux R, Czernin J, Donahue TR, Lavie A, Radu CG.

Cell Chem Biol. 2019 Nov 12. pii: S2451-9456(19)30357-5. doi: 10.1016/j.chembiol.2019.10.012. [Epub ahead of print]

PMID:
31734178
2.

A Conversation Between Uwe Haberkorn and Johannes Czernin.

Haberkorn U, Czernin J.

J Nucl Med. 2019 Nov;60(11):1495-1498. doi: 10.2967/jnumed.119.236760. No abstract available.

PMID:
31676705
3.

What is the best PET target for early biochemical recurrence of prostate cancer?-Authors' reply.

Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Fendler WP, Czernin J.

Lancet Oncol. 2019 Nov;20(11):e609-e610. doi: 10.1016/S1470-2045(19)30654-0. No abstract available.

PMID:
31674314
4.

A Conversation Between Elisabeth de Vries and Johannes Czernin.

de Vries E, Czernin J.

J Nucl Med. 2019 Oct;60(10):1337-1339. doi: 10.2967/jnumed.119.235523. No abstract available.

PMID:
31575716
5.

Total-body 68Ga-PSMA-11 PET/CT for bone metastasis detection in prostate cancer patients: Potential impact on bone scan guidelines.

Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Willliams J, Calais J.

J Nucl Med. 2019 Sep 20. pii: jnumed.119.230318. doi: 10.2967/jnumed.119.230318. [Epub ahead of print]

PMID:
31541035
6.

Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.

Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Hadaschik B.

Clin Cancer Res. 2019 Sep 11. doi: 10.1158/1078-0432.CCR-19-1050. [Epub ahead of print]

PMID:
31511295
7.

A Conversation Between Joanna Fowler and Johannes Czernin.

Fowler JS, Czernin J.

J Nucl Med. 2019 Sep;60(9):1191-1193. doi: 10.2967/jnumed.119.233619. No abstract available.

PMID:
31481591
8.

The Future of Nuclear Medicine as an Independent Specialty.

Czernin J, Sonni I, Razmaria A, Calais J.

J Nucl Med. 2019 Sep;60(Suppl 2):3S-12S. doi: 10.2967/jnumed.118.220558.

PMID:
31481589
9.

EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).

Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K.

Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544. doi: 10.1007/s00259-019-04485-3. Epub 2019 Aug 22.

PMID:
31440799
10.

18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.

Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J.

Lancet Oncol. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30. Erratum in: Lancet Oncol. 2019 Nov;20(11):e613.

PMID:
31375469
11.

A Conversation Between Hedvig Hricak and Johannes Czernin.

Hricak H, Czernin J.

J Nucl Med. 2019 Aug;60(8):1038-1041. doi: 10.2967/jnumed.119.232405. No abstract available.

PMID:
31371619
12.

Toward Independent Nuclear Medicine, Molecular Imaging, and Theranostic Programs.

Czernin J.

J Nucl Med. 2019 Aug;60(8):1037. doi: 10.2967/jnumed.119.233627. No abstract available.

PMID:
31371618
13.

Can the injected dose be reduced in 68Ga-PSMA-11 PET/CT maintaining high image quality for lesion detection?

Rauscher I, Fendler WP, Hope T, Quon A, Nekolla SG, Calais J, Richter A, Haller B, Herrmann K, Weber WA, Czernin J, Eiber M.

J Nucl Med. 2019 Jul 19. pii: jnumed.119.227207. doi: 10.2967/jnumed.119.227207. [Epub ahead of print]

PMID:
31324710
14.

Transforming an Academic Radiochemistry Facility for Positron Emission Tomography Drug cGMP Compliance.

Zhu S, Mosessian S, Kroeger K, Sadeghi S, Slavik R, Kinloch S, Moore M, Allen-Auerbach M, Czernin J, Phelps M.

Mol Imaging Biol. 2019 Jun 25. doi: 10.1007/s11307-019-01395-6. [Epub ahead of print]

PMID:
31240531
15.

A Conversation Between Nora Volkow and Johannes Czernin.

Volkow N, Czernin J.

J Nucl Med. 2019 Jun;60(6):717-720. doi: 10.2967/jnumed.119.229633. No abstract available. Erratum in: J Nucl Med. 2019 Nov;60(11):1648.

PMID:
31160430
16.

Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14-16, 2018; Vienna, Austria.

Lim MS, Beyer T, Babayan A, Bergmann M, Brehme M, Buyx A, Czernin J, Egger G, Elenitoba-Johnson KSJ, Gückel B, Jačan A, Haslacher H, Hicks RJ, Kenner L, Langanke M, Mitterhauser M, Pichler BJ, Salih HR, Schibli R, Schulz S, Simecek J, Simon J, Soares MO, Stelzl U, Wadsak W, Zatloukal K, Zeitlinger M, Hacker M.

Mol Imaging Biol. 2019 May 2. doi: 10.1007/s11307-019-01361-2. [Epub ahead of print]

PMID:
31049831
17.

A Conversation Between Markus Schwaiger and Johannes Czernin.

Schwaiger M, Czernin J.

J Nucl Med. 2019 May;60(5):573-576. doi: 10.2967/jnumed.119.228981. No abstract available.

PMID:
31043502
18.

Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.

Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA.

JAMA Oncol. 2019 Jun 1;5(6):856-863. doi: 10.1001/jamaoncol.2019.0096.

19.

Discussions with Leaders: A Conversation between Simon Cherry and Johannes Czernin.

Cherry SR, Czernin J.

J Nucl Med. 2019 Mar;60(3):295-298. No abstract available.

PMID:
30824670
20.

Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].

Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG.

BMC Cancer. 2019 Jan 21;19(1):97. doi: 10.1186/s12885-019-5297-x.

21.

Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].

Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG.

BMC Cancer. 2019 Jan 7;19(1):18. doi: 10.1186/s12885-018-5200-1. Erratum in: BMC Cancer. 2019 Jan 21;19(1):97.

22.

Discussions with Leaders: A Conversation Between Richard Wahl and Johannes Czernin.

Wahl RL, Czernin J.

J Nucl Med. 2019 Jan;60(1):3-6. doi: 10.2967/jnumed.118.223503. No abstract available.

PMID:
30602594
23.

Delivering Radionuclide Therapies Requires Extensive Training and Competence: Send a Firm Message to the NRC and Your Representatives.

Razmaria A, Calais J, Czernin J.

J Nucl Med. 2019 Jan;60(1):1-2. No abstract available.

PMID:
30602593
24.

Discussions with Leaders: A Conversation Between Sam Gambhir and Johannes Czernin.

Czernin J, Gambhir SS.

J Nucl Med. 2018 Dec;59(12):1783-1785. doi: 10.2967/jnumed.118.221648. No abstract available.

PMID:
30510073
25.

Dosimetry, biodistribution, and safety of flurpiridaz F 18 in healthy subjects undergoing rest and exercise or pharmacological stress PET myocardial perfusion imaging.

Maddahi J, Bengel F, Czernin J, Crane P, Dahlbom M, Schelbert H, Sparks R, Phelps M, Lazewatsky J.

J Nucl Cardiol. 2018 Nov 28. doi: 10.1007/s12350-018-01484-z. [Epub ahead of print]

PMID:
30488323
26.

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.

Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig M, Reiter RE, Herrmann K, Radu CG, Czernin J, Eiber M.

EJNMMI Res. 2018 Oct 29;8(1):96. doi: 10.1186/s13550-018-0451-z.

27.

Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT.

Polverari G, Ceci F, Allen-Auerbach M, Gupta P, Fishbein MC, Reiter RE, Lee JM, Hope TA, Carroll RM, Czernin J, Calais J.

Clin Genitourin Cancer. 2019 Feb;17(1):e53-e55. doi: 10.1016/j.clgc.2018.09.003. Epub 2018 Sep 7. No abstract available.

PMID:
30293922
28.

The Quality and Impact of JNM.

Czernin J.

J Nucl Med. 2018 Sep;59(9):1337. No abstract available.

29.

Is This Whom We Have Become?

Czernin J.

J Nucl Med. 2018 Aug;59(8):1171. No abstract available.

30.

Aetna and 68Ga-DOTATATE: A Sequel to "The Injustice of Being Judged by the Errors of Others".

Czernin J, Ceci F.

J Nucl Med. 2018 May;59(5):721-722. No abstract available.

31.

18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study.

Patel CB, Fazzari E, Chakhoyan A, Yao J, Raymond C, Nguyen H, Manoukian J, Nguyen N, Pope W, Cloughesy TF, Nghiemphu PL, Czernin J, Lai A, Ellingson BM.

J Neurooncol. 2018 Sep;139(2):399-409. doi: 10.1007/s11060-018-2877-6. Epub 2018 Apr 20.

32.

Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer.

Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG.

J Nucl Med. 2018 Nov;59(11):1714-1721. doi: 10.2967/jnumed.118.209387. Epub 2018 Apr 13.

33.

Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer.

Lückerath K, Stuparu AD, Wei L, Kim W, Radu CG, Mona CE, Calais J, Rettig M, Reiter RE, Czernin J, Slavik R, Herrmann K, Eiber M, Fendler WP.

J Nucl Med. 2018 Sep;59(9):1392-1397. doi: 10.2967/jnumed.118.207704. Epub 2018 Mar 30.

34.

The National Oncologic PET Registry (NOPR): A Monumental Effort by a Few Leaders.

Czernin J.

J Nucl Med. 2018 Mar;59(3):379. doi: 10.2967/jnumed.117.207860. No abstract available.

35.

The National Oncology PET Registry (NOPR): A monumental effort by a few leaders.

Czernin J.

J Nucl Med. 2018 Jan 25. pii: jnumed.118.207860. doi: 10.2967/jnumed.118.207860. [Epub ahead of print] No abstract available.

36.

Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence.

Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K.

J Nucl Med. 2018 Mar;59(3):434-441. doi: 10.2967/jnumed.117.202945. Epub 2017 Dec 14.

37.

68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.

Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG.

J Nucl Med. 2018 Feb;59(2):230-237. doi: 10.2967/jnumed.117.201749. Epub 2017 Nov 9.

38.

Is 16 Months of Specialized Nuclear Medicine Training Enough for Best Patient Care?

Czernin J.

J Nucl Med. 2017 Oct;58(10):1535. No abstract available.

39.

Activation of the "Splenocardiac Axis" by electronic and tobacco cigarettes in otherwise healthy young adults.

Boas Z, Gupta P, Moheimani RS, Bhetraratana M, Yin F, Peters KM, Gornbein J, Araujo JA, Czernin J, Middlekauff HR.

Physiol Rep. 2017 Sep;5(17). pii: e13393. doi: 10.14814/phy2.13393.

40.

Detection of immune responses after immunotherapy in glioblastoma using PET and MRI.

Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM.

Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10220-10225. doi: 10.1073/pnas.1706689114. Epub 2017 Sep 5.

41.

ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways.

Le TM, Poddar S, Capri JR, Abt ER, Kim W, Wei L, Uong NT, Cheng CM, Braas D, Nikanjam M, Rix P, Merkurjev D, Zaretsky J, Kornblum HI, Ribas A, Herschman HR, Whitelegge J, Faull KF, Donahue TR, Czernin J, Radu CG.

Nat Commun. 2017 Aug 14;8(1):241. doi: 10.1038/s41467-017-00221-3.

42.

The Impact of the Impact Factor.

Czernin J.

J Nucl Med. 2017 Aug;58(8):1185. No abstract available.

PMID:
28765226
Free Article
43.

Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer.

Fendler WP, Stuparu AD, Evans-Axelsson S, Lückerath K, Wei L, Kim W, Poddar S, Said J, Radu CG, Eiber M, Czernin J, Slavik R, Herrmann K.

J Nucl Med. 2017 Nov;58(11):1786-1792. doi: 10.2967/jnumed.117.193359. Epub 2017 May 25.

44.

Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented.

Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP, Hendifar AE, Pisegna JR, Hecht JR, Wolin EM, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach MS, Herrmann K.

J Nucl Med. 2017 Nov;58(11):1793-1796. doi: 10.2967/jnumed.117.192450. Epub 2017 May 4.

45.

Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail?

Czernin J, Eiber M.

J Nucl Med. 2017 Aug;58(8):1186-1187. doi: 10.2967/jnumed.117.193516. Epub 2017 May 4. No abstract available.

46.

68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study.

Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, Gupta P, Hartenbach M, Hope TA, Okamoto S, Pfob CH, Pöppel TD, Rischpler C, Schwarzenböck S, Stebner V, Unterrainer M, Zacho HD, Maurer T, Gratzke C, Crispin A, Czernin J, Herrmann K, Eiber M.

J Nucl Med. 2017 Oct;58(10):1617-1623. doi: 10.2967/jnumed.117.190827. Epub 2017 Apr 13.

47.

Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma.

Keu KV, Witney TH, Yaghoubi S, Rosenberg J, Kurien A, Magnusson R, Williams J, Habte F, Wagner JR, Forman S, Brown C, Allen-Auerbach M, Czernin J, Tang W, Jensen MC, Badie B, Gambhir SS.

Sci Transl Med. 2017 Jan 18;9(373). pii: eaag2196. doi: 10.1126/scitranslmed.aag2196.

48.

Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.

Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, Graeber T, Jackson NJ, Czernin J, Emberley E, Gross M, Janes J, Mackinnon A, Pan A, Rodriguez M, Works M, Zhang W, Parlati F, Demo S, Garon E, Krysan K, Walser TC, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB.

Cell Rep. 2017 Jan 17;18(3):601-610. doi: 10.1016/j.celrep.2016.12.061.

49.

The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis.

Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L, Eiber M, Herrmann K, Fendler WP.

J Nucl Med. 2017 May;58(5):756-761. doi: 10.2967/jnumed.116.185587. Epub 2017 Jan 12. Review.

50.

Molecular Imaging and Therapy with a Purpose: A Renaissance of Nuclear Medicine.

Czernin J.

J Nucl Med. 2017 Jan;58(1):21A-22A. No abstract available.

Supplemental Content

Loading ...
Support Center